Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Anja Rinke, Hans-Helge Müller, Carmen Schade-Brittinger, Klaus-Jochen Klose, Peter Barth, Matthias Wied, Christina Mayer, Behnaz Aminossadati, Ulrich-Frank Pape, Michael Bläker, Jan Harder, Christian Arnold, Thomas Gress, and Rudolf Arnold

Journal of Clinical Oncology. 2009 Oct 1; 27(28): 4656-63

Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.

Comprehensive description of neuroendocrine tumors: symptoms, diagnosis and treatment. Presented here with permission from Dr. Demeure.
Michael J. Demeure, MD, MBA
Senior Investigator
Endocrine & Cancer Surgery
Scottsdale, AZ

Print Friendly, PDF & Email